Focused On-demand Library for DNA-directed RNA polymerases I and III subunit RPAC1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O15160

UPID:

RPAC1_HUMAN

Alternative names:

AC40; DNA-directed RNA polymerases I and III 40 kDa polypeptide; RPA39; RPC40

Alternative UPACC:

O15160; O75395; Q5JTE3

Background:

DNA-directed RNA polymerases I and III subunit RPAC1, known by alternative names such as AC40, RPA39, and RPC40, plays a pivotal role in the transcription of DNA into RNA. It is a common component of RNA polymerases I and III, crucial for synthesizing ribosomal RNA precursors and small RNAs, including 5S rRNA and tRNAs. The protein is integral to the Pol core element, featuring a large central cleft and a dynamic clamp element essential for the transcription process.

Therapeutic significance:

RPAC1's involvement in Treacher Collins syndrome 3 and Leukodystrophy, hypomyelinating, 11, underscores its critical role in craniofacial development and neurological function. Understanding the role of RPAC1 could open doors to potential therapeutic strategies for these conditions, highlighting the importance of targeted research in uncovering novel treatment avenues.